Previous Close | 15.57 |
Open | 15.56 |
Bid | 15.18 x 1100 |
Ask | 15.25 x 400 |
Day's Range | 15.15 - 15.60 |
52 Week Range | 6.46 - 35.67 |
Volume | |
Avg. Volume | 4,573,057 |
Market Cap | 2.349B |
Beta (5Y Monthly) | 2.33 |
PE Ratio (TTM) | 169.00 |
EPS (TTM) | 0.09 |
Earnings Date | Apr 29, 2024 - May 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.43 |
Subscribe to Yahoo Finance Plus to view Fair Value for TGTX
It is hard to get excited after looking at TG Therapeutics' (NASDAQ:TGTX) recent performance, when its stock has...
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at htt